tbuckley/cabot-search huggingface dataset:
Erosive Deforming Inflammatory Arthritis in a Patient With Cervical Adenocarcinoma
Authors: Ananta Subedi, Julius Strauss, Sarthak Gupta
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Longer Survival With Anti–Programmed Cell Death 1 and Development of Cutaneous Toxic Effects, an Expected Association—In Reply
Authors: Douglas B. Johnson, Fei Ye, Anna K. Dewan
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
TCT-410 Assessing Suitability for Short-Term DAPT: Thromboresistance, Albumin Retention, and Endothelial Function in the Resolute Onyx Zotarolimus Versus BioFreedom Biolimus-Eluting Coronary Stent Systems
Authors: Hiroyuki Jinnouchi, Frank Kolodgie, Qi Cheng, Anne Cornelissen, Christine Janifer, Atsushi Sakamoto, Yu Sato, Liang Guo, Stefan Tunev, Renu Virmani, Aloke Finn
Journal: Journal of the American College of Cardiology (2019)
C-Met activation is associated with Gemcitabine chemoresistance of pancreatic tumor cells in culture.
Authors: Ami Shah, Justin Summy, Jing Zhang, Nila Parikh, Gary Gallick
Journal: Cancer Research (2007)

2334  Pancreatic cancer afflicts nearly 32,000 people in the USA yearly and has an extremely poor prognosis. The five-year survival rate is less than 5%, due largely to late presentation and resistance to standard therapies. Gemcitabine is currently the standard of care for unresectable tumors; however resistance to gemcitabine quickly emerges. To study mechanisms by which resistance arises in pancreatic tumors, we have isolated two gemcitabine resistant (GR) stable cell lines from the human pancreatic cancer line L3.6pl and AsPC-1. These cells were resistant to gemcitabine compared to the parental cell lines by 50 and 100 fold respectively. They were also resistant to EGFR and c-Met inhibition but were equally sensitive to oxaliplatin and 5-FU. GR cells were more migratory and invasive than parental cells lines. Because of the increased intrinsic migratory ability, we examined the status of c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), as c-Met is activated in 70% of human pancreatic cancers. There was a constitutive increase in the phosphorylation of the c-Met receptor, in both cell lines, while total levels were unchanged. Addition of HGF to the GR cells did not further increase receptor phosphorylation. Also, while the parental cell lines could be stimulated to migrate and invade with HGF, no change in migration or invasion was noted with addition of HGF to the GR cells. While c-Met activation was not associated with increased Src or Akt phosphorylation, GR cells acquired changes characteristic of epithelial to mesenchymal transition (EMT), including an increase in nuclear β-catenin and vimentin and a decrease in E-cadherin expression. As c-Met activation is associated with nuclear translocation of β-catenin and EGFR phosphorylation, our data suggest that c-Met activation may be an important mechanism leading to gemcitabine resistance, EGFR inhibitor resistance and tumor progression in pancreatic carcinoma. The mechanistic basis for c-Met activation is currently under investigation.
TCT-463 Transcatheter Mitral Valve Replacement in a Series of 10 Compassionate-Use Cases With Mid-Term Follow-Up
Authors: Sebastian Ludwig, Florian Deuschl, Daniel Kalbacher, Niklas Schofer, Oliver Bhadra, Andreas Schäfer, Matthias Linder, Yvonne Schneeberger, Lara Waldschmidt, Moritz Seiffert, Johannes Schirmer, Dirk Westermann, Hermann Reichenspurner, Stefan Blankenberg, Ulrich Schäfer, Lenard Conradi
Journal: Journal of the American College of Cardiology (2019)
Circles in the heart and cardiovascular system
Authors: Tingsen Benson Lim, Annadoray Lavenniah, Roger Sik-Yin Foo
Journal: Cardiovascular Research (2019)

The combination of next-generation sequencing, advanced bioinformatics analysis, and molecular research has now established circular RNAs (circRNAs) as a heterogeneous group of non-coding RNA that is widely and abundantly expressed. CircRNAs are single-stranded RNA, covalently backspliced to form closed circular loops. Different models of back-splicing have been proposed, and mechanisms for circRNA function include sequestering microRNAs, direct interaction with proteins, regulation of transcription, and translation. Exploring the role of circRNAs in different disease settings, and understanding how they contribute to disease progression promises to provide valuable insight into potential novel therapeutic approaches. Here, we review the growing number of published research on circRNAs in the heart and cardiovascular system and summarize the circRNAs that have been implicated in disease.
SAT0061 Haq score is an independent predictor of sustained remission in patients with rheumatoid arthritis
Authors: S-S Lee, J-H Kang, J-E Kim, K-E Lee, D-J Park
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> We compared remission rates, according to different definitions of remission in rheumatoid arthritis (RA) and investigated the potential predictors of sustained remission at the 2-year follow-up. <h3>Methods</h3> We obtained data on 291 RA outpatients, seen from July 2009 to September 2012. Sociodemographic data and answers to questionnaires were collected in face-to-face interviews. Remission was defined according to the Disease Activity Score in 28 joints (DAS28)-ESR, DAS28-CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and ACR/EULAR Boolean definition. Sustained remission was defined as when the patient continued in remission at two consecutive annual assessments. Predictors of sustained remission according to the DAS28-CRP were assessed by univariate and multivariate analyses. <h3>Results</h3> For the 291 RA patients, the remission rates of RA were 17.9% (DAS28-ESR), 54.3% (DAS28-CRP), 10.3% (SDAI), 10.0% (CDAI), and 5.8% (Boolean). On follow-up for 2 years, the sustained remission rates of RA were 46.5% (DAS28), 55.0% (DAS28-CRP), 37.5% (SDAI), 32.0% (CDAI), and 30.8% (Boolean). RA patients who achieve sustained remission according to the DAS28-CRP were younger, and had more education, higher monthly income, lower Health Assessment Questionnaire (HAQ) score, lower physician global assessment, lower patient global assessment, lower patient pain assessment, and higher EQ-5D. In multivariate analysis, only the HAQ score predicted sustained remission according to DAS28-CRP (OR=0.257, 95% CI 0.067–0.980, <i>p</i> =0.047). <h3>Conclusions</h3> The remission rates of RA patients differed according to the definition of remission, and the highest sustained remission rate was classified by the DAS28-CRP. A lower HAQ score was an independent predictor of sustained remission over 2 years, according to the DAS28-CRP. <h3>Disclosure of Interest</h3> None declared
A “balloon” inside the mouth
Authors: Koichi Tsunoda, Naoaki Ishikawa, Mihiro Takazawa, Kazuyo Yagishita, Sota Oguro
Journal: Endoscopy (2019)

A 29-year-old woman found what looked like a balloon inside her mouth when she checked her mouth with a mirror after a dental check-up. There was no symptom except the “balloon” behind her tongue; she was surprised and worried about the strange experience. She had no history of drinking or smoking.
Extent And Impact Of Late Versus Early COPD Diagnosis In Women In The Swedish Arctic Study
Authors: Karin Lisspers, K. Larsson, Christer Janson, Björn Ställberg, F. S. Gutzwiller, K. Mezzi, M. Uhde, L. Jorgensen, Gunnar Johansson
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
TCT-395 Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding and Ischemia in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial
Authors: Young Bin Song, Ki Hong Choi, Taek Kyu Park, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Joo-Yong Hahn
Journal: Journal of the American College of Cardiology (2019)
TCT-532 Impact of New Pacemaker in Patients Undergoing TAVR: A Report From the National SWENTRY and Swedish ICD and Pacemaker Registries
Authors: Oskar Angerås, Dan Ioanes, Andreas Rück, Thomas Kellerth, Johan Nilsson, Matthias Götberg, Niels Erik Nielsen, Fredrik Gadler, Piotr Szamlewski, Stefan James, Truls Råmunddal, Elmir Omerovic, Petur Petursson
Journal: Journal of the American College of Cardiology (2019)
Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer (TNBC).
Authors: Esther H. Lips, Magali Michaut, Lennart Mulder, Nicolle Besselink, Marlous L. Hoogstraat, Marco J. Koudijs, Emile E. Voest, Rene Bernards, Jelle Wesseling, Lodewyk F. A. Wessels, Sjoerd Rodenhuis
Journal: Journal of Clinical Oncology (2013)

1010 Background: In TNBC initial response to chemotherapy is often favorable, but relapse and chemotherapy resistance frequently occur in advanced disease. Hence there is an urgent need for targeted treatments in this breast cancer subtype. Methods: To identify biomarkers of chemotherapy resistance and putative directed treatment targets, we performed next generation sequencing (NGS) of 2,000 genes implicated in oncogenesis. DNA from 31 pre-treatment biopsies and matched normal blood was sequenced. Biopsies were derived from patients scheduled to receive neoadjuvant chemotherapy with doxorubicin/cyclophosphamide. For the analysis, the tumors were divided in responders and non-responders, depending on whether or not a pathological complete remission (pCR) was achieved. Two definitions of pCR were employed: either the complete absence of infiltrating tumor cells in the breast (n=18) or a pCR of both the breast and lymph nodes (n=15). Tumors with partial or no responses were grouped in the non-responder category. Results: As a positive control, we verified that all patients with a known germline BRCA1 mutation (n=8) could be detected by the NGS analysis. In further analyses, we focused only on somatic mutations. Overall, the mutation rate was slightly higher in the non-responders (per tumor, average=12, range=[3-25]) than in the responders (average=8, range=[3-19]) (p=0.17). The analysis of individual genes did not reveal significant differences between responders and non-responders. However, pathway analysis showed that mutations in phosphatidylinositol signaling (e.g., PIK3CA, CALML5) were significantly more frequent in the non-responders, with mutations present in 10/13 non-responders and 2/18 responders (adjusted p=0.013). The chemokine and integrin signaling pathways also revealed a significantly higher mutation rate in the non-responders. Conclusions: Mutations in genes of the phosphatidylinositol pathway occur frequently in TNBCs that do not achieve a pCR on a neoadjuvant chemotherapy regimen consisting of doxorubicin and cyclophosphamide. After validation, alternative chemotherapy regimens and targeted agents should be investigated for these tumors.
TCT-218 The Efficacy and Safety of Transradial and Transfemoral Approach in Treatment of Coronary Chronic Total Occlusion: A Systematic Review and Meta-Analysis
Authors: Mohamad Soud, Ziad SayedAhmad, Marvin Kajy, Yasser Al-khadra, Fahed Darmoch, Homam Moussa Pacha, Zeel Shah, Rajiv Tayal, Amir Kaki, Babar Basir, M. Chadi Alraies
Journal: Journal of the American College of Cardiology (2019)
TCT-484 Prognostic Impact of Subclinical Hemoglobin Descents in Patients Undergoing Primary Angioplasty
Authors: Alfredo Redondo Dieguez, Ana Belen Cid Alvarez, Charigan Abou Jokh Casas, Diego López Otero, Ramiro Trillo Nouche
Journal: Journal of the American College of Cardiology (2019)
TCT-184 Early Scaffold Disruption and Late Structural Discontinuity After Implantation of the Aptitude Sirolimus-Eluting Bioresorbable Scaffold in Normal Porcine Coronary Arteries: An OCT Study
Authors: Yanping Cheng, Marco Ferrone, Jenn McGregor, Gerard Conditt, Grzegorz Kaluza, Juan Granada
Journal: Journal of the American College of Cardiology (2019)
TCT-520 Optimal Timing of Coronary Intervention in Patients Who Survived Cardiac Arrest Without ST-Segment Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Authors: Mahmoud Barbarawi, Yazan Zayed, Babikir Kheiri, Owais alBarbarawi, Ahmad Al-Abdouh, Harsukh Dhillon, Ghassan Bachuwa, Mohammad Luay Alkotob
Journal: Journal of the American College of Cardiology (2019)
Errors in Statistical Programming for Study About Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer
Authors: Natalie J. Engmann
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abdominal Surgery of Infancy and Childhood
Journal: JAMA (1941)

1. General Management Considerations 2. The Alimentary Tract in Newborns 3. The Alimentary Tract in Older Infants and Children 4. The Liver, Biliary Tract, Pancreas, Spleen and Adrenal Glands 5. Abdominal Tumours 6. Abdominal Trauma
Expression of N-myc downregulated gene-1 attenuates pancreatic cancer cell growth
Authors: Eliane Angst, Sascha Hasan, Melvie Kim, Aihua Li, Beat Gloor, Howard Reber, Oscar Hines, Guido Eibl
Journal: Cancer Research (2008)

1943  The study of N-myc downregulated gene-1 (Ndrg1, Cap43, RIT42), a 43 kDa protein, in tumor growth and metastasis has recently gained interest as a potential therapeutic target. Although its function and molecular signals are largely unknown, loss of Ndrg1 expression in colon cancer is associated with a more aggressive tumor phenotype and more metastatic spread. In human pancreatic cancers the expression of Ndrg1 is correlated with better differentiated tumors and improved clinical outcome. The aim of the present study was to elucidate the functional role of Ndrg1 in human pancreatic cancer cells in vitro. Six human pancreatic cancer cells lines (AsPC-1, BxPC-3, Capan-2, HPAF-II, MiaPaCa-2, and Panc-1) with varying degree of differentiation were screened for Ndrg1 mRNA and protein expression by real time PCR and Western blotting. Ndrg1 transcripts and proteins were detected in all cell lines with a strongest expression in the moderately differentiated cell line BxPC-3. To clearly delineate the functional role of Ndrg1 in pancreatic cancer cells, HPAF-II cells, displaying weak Ndrg1 expression, were transfected with the full-length Ndrg1 cDNA cloned into the pcDNA3.1+ vector. Stable cell clones were selected with neomycin. Successful transfection was confirmed by real-time PCR and Western blotting, which demonstrated marked over-expression of Ndrg1. Stable expression of Ndrg1 was verified by repeated protein measurements of cell clones growing in culture for up to four weeks. Three separate clones expressing either Ndrg1 or the control vector were analyzed for cell growth using cell count and MTT assay for 24 to 96 hours. While HPAF-II clones stably expressing the empty vector showed a 457±44% increase in cell count at 96 hours, Ndrg1-expressing HPAF-II cells demonstrated a 241±57% increase (p 2-fold decrease or increase in gene expression) difference in 14 genes, most of them with known functions in intercellular adhesion (e.g. CD44, E-cadherin, ITGB3) and matrix degradation (e.g. MMP10, MMP11). In summary we found that expression of Ndrg1 correlated with reduced cell growth in human pancreatic cancer cells. In addition, gene array analysis detected differences in several metastasis-related genes, suggesting a functional role for Ndrg1 in pancreatic cancer cell adhesion and invasion.
Endogenous STAT3-Activated Wnt5a Provides CLL Cells with Survival Advantage
Authors: Uri Rozovski, Ping Li, David M. Harris, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan A. Burger, Prithviraj Bose, Philip A. Thompson, Nitin Jain, William G. Wierda, Michael J. Keating, Zeev E. Estrov
Journal: Blood (2018)
Phase II study of S-1 and biweekly docetaxel combination in advanced or recurrent gastric cancer
Authors: Y. Kakeji, E. Oki, K. Nishida, T. Koga, E. Tokunaga, M. Morita, Y. Emi, Y. Maehara
Journal: Journal of Clinical Oncology (2006)

14031 Background: Docetaxel (TXT) and S-1 are active agents against gastric cancer. A synergistic antitumor effect has been shown in a preclinical study (Takahashi et al., Oncology 2005), and our previous phase I trial demonstrated the safety and tolerability of the combination, and its potent activity. To prospectively evaluate toxicity and efficacy of S-1/ biweekly TXT, we conducted the current phase II study in patients with advanced and recurrent gastric cancer. Methods: Patients (pts) with advanced or recurrent gastric cancer, who have not received any chemotherapy except postoperative chemotherapy (not including S-1 or TXT), were eligible for the trial, and were treated with docetaxel 35 mg/m 2 one hour iv infusion on day 1 and 15, and S-1 at a full dose of 80 mg/m 2 /day for two weeks every four weeks. Results: Thirty-five pts with measurable lesions (RECIST) (10 females, 25 males; performance status [PS] 0/1/2: 23/8/4, age 27–74, differentiated/undifferentiated adenocarcinoma: 19/16) have been enrolled. A total of 113 cycles were administered (median 3, range 1–6), and all pts were assessable for toxicity and efficacy. Grade 3–4 toxicities were: neutropenia in 20.0% (grade 4: 11.4%) of patients, leukocytopenia in 11.4% (grade 4: 0%), anemia in 5.7%, appetite loss in 8.6%, stomatitis in 8.6%, fever in 2.9%, and fatigue in 2.9%. All treatment related toxicities resolved, and no toxic death was reported. Thirteen partial responses (PR) were obtained, resulting in an overall response (OR) rate of 37.1% (95% CI: 0.22–0.55). Thirteen pts (37.5%) had stable disease, and 4 pts (12.5%) progressed. The tumor control rate was 74.3% (95% CI: 0.57–0.88). The median survival time (MST) and time to treatment failure (TTF) were 326 and 75 days, respectively. Conclusions: The combination of S-1/ biweekly TXT is active in advanced or recurrent gastric cancer, and can be given safely with proper management of adverse events even in outpatient clinic. S-1/ biweekly TXT is one of the most effective regimen to control metastatic gastric cancer with less toxicity. No significant financial relationships to disclose.
TCT-304 1-Year Clinical Outcomes in Patients Implanted With Biodegradable Polymer Coated Ultrathin Strut Sirolimus-Eluting Coronary Stent System for the Treatment of Very Long (≥40-mm) Lesions
Authors: Mohit Gupta, Vishal Batra, Girish MP, Ankit Bansal, Sanjay Tyagi
Journal: Journal of the American College of Cardiology (2019)
TCT-53 Impact of Intravascular Ultrasound Utilization on Outcomes Following Percutaneous Coronary Intervention for In-Stent Restenosis
Authors: Evan Shlofmitz, Rebecca Torguson, Cheng Zhang, Aaphtaab Dheendsa, Nauman Khalid, Yuefeng Chen, Anees Mussalam, Toby Rogers, Hayder Hashim, Nelson Bernardo, Itsik Ben-Dor, Lowell Satler, Hector Garcia-Garcia, Ron Waksman
Journal: Journal of the American College of Cardiology (2019)
Anti-oxidant activity reinforced reduced graphene oxide/alginate microgels: Mesenchymal stem cell encapsulation and regeneration of infarcted hearts
Authors: Goeun Choe, Seon-Wook Kim, Junggeon Park, Junha Park, Semin Kim, Yong Sook Kim, Youngkeun Ahn, Da-Woon Jung, Darren R. Williams, Jae Young Lee
Journal: Biomaterials (2019)